Company intelligence / Profile preview

Biostate AI

Ownership: Private
Development stage: Commercial

Overview

Biostate AI has developed proprietary technologies to dramatically reduce the cost of high-throughput RNA sequencing. Their integrated platform combines sample processing, automation, cloud-based data management, and generative AI to build what they claim will be the world’s largest transcriptomic database. Early proof-of-concept studies include predicting leukemia recurrence before symptoms appear. The company is expanding into oncology, autoimmune disease, and cardiovascular collaborations with leading academic medical centers. No clinical trial results have been published yet.

Therapeutic areas: OncologyCardiovascularImmunology
Modalities: RNA sequencing platform
Industry: Molecular Diagnostics

Partnerships

MD Anderson Cancer CenterWeill Cornell MedicineStanford MedicineMassachusetts General Hospital

Beyond the preview

Go deeper on Biostate AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biostate AI.

Explore the full profile